Zealand Pharma A/S Stock News

Zealand Pharma shares popped on Friday on positive weight loss results from long-acting amylin analog petrelintide. The company said petrelintide may produce similar weight loss results and a "better

Shares of Zealand Pharma soared on Friday after the Danish biotech company reported positive results from a trial of its experimental weight-loss injection, that could compete with popular GLP-1s drug

Zealand Pharma said on Thursday an early-stage study showed a high dose of its drug helped reduce weight by an average 8.6% after 16 weekly doses.

Company announcement – No. 32 / 2024 Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide Bo

Denmark's Zealand Pharma said on Thursday its experimental weight-loss drug showed an improvement in patients with a type of fatty liver disease after results from a mid-stage study were leaked, sendi

Zealand Pharma A/S (OTCPK:ZLDPF) Q1 2024 Results Conference Call May 16, 2024 8:00 AM ET Company Participants Anna Krassowska - VP, IR Adam Steensberg - President, CEO David Kendall - CMO Henriette We

Positive results achieved in phase 2 study using survodutide for the treatment of patients with MASH; Primary endpoint of histological improvement of MASH met with statistical significance. The global

Novo Nordisk's $600 billion valuation makes it one of the top healthcare companies in the world. For investors looking for stocks with more upside, upstart Zealand Pharma may fit the bill.

Adam Steensberg, Zealand Pharma CEO, joins 'Money Movers' to discuss the goal for the company's weight loss drugs, the company's drug around liver disease, and more.

Zealand Pharma A/S (ZEAL) Q4 2023 Earnings Call Transcript

Company Announcement – No. 10 / 2024 Zealand Pharma convenes its Annual General Meeting 2024 Notice to convene the Annual General Meeting of Zealand Pharma A/S (CVR no.

Zealand Pharma shares jumped 20% after an experimental obesity treatment it is developing with Boehringer Ingelheim yielded "groundbreaking" Phase II trial results in the treatment of fatty liver.

The obesity drugs that powered huge investor gains in 2023 are poised to inspire more corporate dealmaking, scientific breakthroughs and better patient access in the year ahead, analysts say.

Zealand Pharma A/S (ZEAL) Q3 2023 Earnings Conference Call November 9, 2023 8:00 AM ET Company Participants Anna Krassowska - Vice President-Investor Relations Adam Steensberg - President & Chief Exec

Drug developers are chasing an obesity drug gold rush that may be worth up to $100 billion by rolling out treatments that can help lose as much as 24% of weight in less than a year.